Business
Resolution of Allegations of Patent Infringement
Resolution of Allegations of Patent Infringement.
About this update from Incanthera Plc
[{"type":"text","content":"\n\n \n\n \n25 March 2025\n \nIncanthera plc\n(\"Incanthera\" or the \"Company\")\nSuccessful Resolution of Allegations of Patent Infringement\n \nIncanthera plc (AQSE: INC), the Company focused on innovative technologies in dermatology and oncology, is pleased to announce the successful resolution of allegations of patent infringement in relation to the formulation of its premium skin care range, Skin + Cell.\n \nFurther to the Company's announcement of 26 November 2024, the Company can now advise that, following detailed discussions with the third party, a confidential Settlement Agreement (the \"Agreement\") has been reached which, inter alia, provides legal certainty that there has been no patent infringement and no legal proceedings will be started or issued against the Company in relation to Skin + Cell in the future.\n \nThe Agreement enables the Company to progress its plans to bring Skin + CELL to market. The Company is currently engaged in discussions with multiple groups, exploring various market entry strategies, with the potential for global reach.\n \nThe Company will update the market further on these discussions in due course.\n \nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is...